Related Experiment Video

Updated: Aug 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

[Carvedilol in combined therapy of patients with Q myocardial infarction]

V S Sadionchenko, M S Iakovleva, G G Shekhian

    Terapevticheskii Arkhiv
    |October 7, 2005
    PubMed

    Insights

    Carvedilol improved cardiac function and exercise tolerance in patients with Q-wave myocardial infarction (QMI) and heart failure. This beta-blocker therapy reduced microcirculatory stasis and inhibited adverse cardiac remodeling post-MI.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Background:

    • Acute myocardial infarction (MI) often leads to cardiac dysfunction and heart failure.
    • Beta-adrenergic blockers are standard therapy, but their comparative effects on microcirculation and remodeling require further investigation.
    • Carvedilol, a non-selective beta-blocker with alpha-1 blocking activity, has shown promise in cardiovascular conditions.

    Purpose of the Study:

    • To compare the effects of carvedilol versus atenolol on central hemodynamics, microvascular function, hemorheology, and von Willebrand factor (VWF) activity in patients with Q-wave myocardial infarction (QMI) and heart failure.
    • To evaluate the clinical efficacy and impact on exercise tolerance of carvedilol compared to atenolol in the post-MI period.
    • To assess the influence of these beta-blockers on post-infarctional cardiac remodeling.

    Main Methods:

    • A randomized trial involving 90 patients with acute QMI and cardiac failure, divided into three groups: carvedilol, atenolol, and a control group without beta-blockers.
    • Utilized clinical examination, echocardiography, laser Doppler flowmetry (LDF), Holter ECG monitoring, platelet-vessel hemostasis assays, VWF activity measurement, and treadmill testing.
    • Patients were followed for approximately 60 days, with statistical analysis performed using Excel 7.0.

    Main Results:

    • Both carvedilol and atenolol significantly improved treatment efficacy in QMI patients with heart failure.
    • Carvedilol demonstrated superior effects in reducing microcirculatory stasis and correcting abnormal microhemodynamic responses to sympathetic activation.
    • Carvedilol effectively inhibited post-infarctional cardiac remodeling and improved exercise tolerance, as evidenced by treadmill test results.

    Conclusions:

    • Beta-blocker therapy, particularly with carvedilol, is crucial for improving outcomes in QMI patients with heart failure.
    • Carvedilol offers significant benefits by improving microvascular function, reducing cardiac remodeling, and enhancing exercise capacity.
    • The antianginal and anti-ischemic properties of carvedilol contribute to its high clinical efficacy in this patient population.
    Abstract

    More Related Videos

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...